MDR1C3435T基因多态性对辛伐他汀稳态血药浓度及降脂疗效的影响

发布时间：2018-03-04 23:19

本文选题：MDRCT　切入点：基因多态性　出处：《中国医院药学杂志》2017年18期 　论文类型：期刊论文

【摘要】：目的:研究高脂血症患者MDR1C3435T基因分布及其基因多态性对辛伐他汀稳态血药浓度及降脂疗效的影响。方法:115名高脂血症患者均给予每天20 mg的辛伐他汀治疗4周,在给药前及给药4周后取血样,采用PCR-RFLP(聚合酶链反应-限制性片段长度多态性分析)基因检测技术对MDR1C3435T等位基因进行分析,应用全自动生化分析仪和高效液相色谱仪分别测定血脂及辛伐他汀稳态血药浓度。结果:115名高脂血症患者MDR1C3435T基因型分布符合Hardy-Weinberg遗传平衡(P0.05),MDR1C3435T等位基因突变率为40.87%。野生纯合子基因(CC)型组、突变杂合子(CT)型组、突变纯合子(TT)型组之间辛伐他汀稳态血药浓度及降脂疗效无统计学差异(P0.05)。结论:未发现MDR1C3435T基因多态性对辛伐他汀稳态血药浓度及降脂疗效有明显影响。
[Abstract]:Objective: To study the effect of the distribution of patients with hyperlipidemia and MDR1C3435T gene polymorphism on simvastatin steady-state plasma concentration and lipid-lowering efficacy. Methods: the treatment of 115 patients with hyperlipidemia were given simvastatin 20 mg daily for 4 weeks. The blood samples were taken before administration and after 4 weeks of treatment with PCR-RFLP (fragment analysis length polymorphism analysis of polymerase chain reaction restriction) gene detection technique of MDR1C3435T allele, using automatic biochemical analyzer and HPLC steady-state plasma concentration of lipids and simvastatin were measured. Results: the distribution of 115 hyperlipidemia patients with genotype MDR1C3435T with Hardy-Weinberg genetic equilibrium (P0.05), MDR1C3435T allele the mutation rate of 40.87%. gene homozygous wild type (CC) group, mutation heterozygote (CT) group, homozygote (TT) group between simvastatin steady-state plasma concentration and lipid lowering therapy There was no statistical difference (P0.05). Conclusion: no MDR1C3435T gene polymorphism was found to have a significant effect on the steady state blood drug concentration and lipid lowering effect of simvastatin.

【作者单位】：三门峡市中心医院药学部;郑州大学基础医学院药理学教研室;
【分类号】：R969

【相似文献】